After Hours Summary: President Trump has extended pause on attacking Iran energy facilities to April 6, according to CNBC; U +13.8% sharply higher after raising guidance; AGX +9.8% higher on earnings; ACOG -8.1% lower on earnings
After Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: U +13.8% (guidance; also to sunset ironSource Ads Network), IMDX +10.5% (also submits GraftAssureDx for FDA review), AGX +9.8%, VERI +9.2% (guidance; also strategic deal with ORCL), NMAX +6.2%, OXM +1.3%
Companies trading higher in after hours in reaction to news: SIGA +9.9% (declares special cash dividend of $0.60/share), SSRM +1.9% (expects Q1 charge related to sale of Çöpler mine), BE +1.5% (appoints new CFO), CRDO +1.3% (reaches a cross-license and settlement agreement with Molex), RPD +0.9% (acquires Kenzo Security), RUM +0.6% (names new CFO), VG +0.5% (co and Edison announce Calcasieu Pass arbitration settlement), IPSC +0.5% (files prospectus supplement relating to a sales agreement; may offer up to $150 mln of common stock), AAPL +0.4% (report it has discontinued the Mac Pro, according to 9to5mac.com), AMZN +0.2% (Amazon AI chip product leader exits, according to The Information), BA +0.2% (awarded a $326 mln Army contract), NOC +0.2% (awarded a $127 mln Navy contract), MSFT +0.1% (OpenAI surpasses $100 mln annualized revenue from ads pilot, according to TheInformation)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: ACOG -8.1%, DBVT -2%, SKYX -1.4% (also files $200 mln mixed shelf offering), SGP -0.6%, BTGO -0.1%
Companies trading lower in after hours in reaction to news: DTCX -28.8% (stock offering; prices offering at $2/share), ZBIO -9.7% (convertible note and stock offering), PAR -3.7% (files mixed securities shelf offering), VTS -3.5% (names new CEO), ABOS -2.4% (stock offering by selling shareholders), IRON -1.6% (completes enrollment of Phase 3 APOLLO trial of bitopertin), KYTX -1.2% (files for $300 mln mixed securities shelf offering), NUVB -0.5% (European Medicines Agency accepts Market Authorization Application for Taletrectinib), RTX -0.1% (awarded a $773.5 mln modification to Missile Defense Agency contract; also awarded a $193.2 mln modification to Missile Defense Agency contract)